Tom20 gates PINK1 activity and mediates its tethering of the TOM and TIM23 translocases upon mitochondrial stress.

PINK1 mitochondrial import mitochondrial quality control mitophagy proteolysis

Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
05 Mar 2024
Historique:
medline: 28 2 2024
pubmed: 28 2 2024
entrez: 28 2 2024
Statut: ppublish

Résumé

Mutations in PTEN-induced putative kinase 1 (PINK1) cause autosomal recessive early-onset Parkinson's disease (PD). PINK1 is a Ser/Thr kinase that regulates mitochondrial quality control by triggering mitophagy mediated by the ubiquitin (Ub) ligase Parkin. Upon mitochondrial damage, PINK1 accumulates on the outer mitochondrial membrane forming a high-molecular-weight complex with the translocase of the outer membrane (TOM). PINK1 then phosphorylates Ub, which enables recruitment and activation of Parkin followed by autophagic clearance of the damaged mitochondrion. Thus, Parkin-dependent mitophagy hinges on the stable accumulation of PINK1 on the TOM complex. Yet, the mechanism linking mitochondrial stressors to PINK1 accumulation and whether the translocases of the inner membrane (TIMs) are also involved remain unclear. Herein, we demonstrate that mitochondrial stress induces the formation of a PINK1-TOM-TIM23 supercomplex in human cultured cell lines, dopamine neurons, and midbrain organoids. Moreover, we show that PINK1 is required to stably tether the TOM to TIM23 complexes in response to stress such that the supercomplex fails to accumulate in cells lacking PINK1. This tethering is dependent on an interaction between the PINK1 N-terminal-C-terminal extension module and the cytosolic domain of the Tom20 subunit of the TOM complex, the disruption of which, by either designer or PD-associated PINK1 mutations, inhibits downstream mitophagy. Together, the findings provide key insight into how PINK1 interfaces with the mitochondrial import machinery, with important implications for the mechanisms of mitochondrial quality control and PD pathogenesis.

Identifiants

pubmed: 38416681
doi: 10.1073/pnas.2313540121
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2313540121

Subventions

Organisme : Michael J. Fox Foundation for Parkinson's Research (MJFF)
ID : #18293

Déclaration de conflit d'intérêts

Competing interests statement:J.-F.T. was a member of the scientific board of Mitokinin Inc. at the time of submission. When Mitokinin Inc. was later acquired, he received financial compensation for this consultancy work and is no longer connected with the company.

Auteurs

Mohamed A Eldeeb (MA)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Andrew N Bayne (AN)

Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.
Department of Pharmacology and Therapeutics, McGill University, Montréal, QC H3G 1Y6, Canada.
Centre de Recherche en Biologie Structurale, Montréal, QC H3G 0B1, Canada.

Armaan Fallahi (A)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Thomas Goiran (T)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Emma J MacDougall (EJ)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Andrea Soumbasis (A)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Cornelia E Zorca (CE)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Jace-Jones Tabah (JJ)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Rhalena A Thomas (RA)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Nathan Karpilovsky (N)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Meghna Mathur (M)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Thomas M Durcan (TM)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Jean-François Trempe (JF)

Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.
Department of Pharmacology and Therapeutics, McGill University, Montréal, QC H3G 1Y6, Canada.
Centre de Recherche en Biologie Structurale, Montréal, QC H3G 0B1, Canada.

Edward A Fon (EA)

McGill Parkinson Program and Neurodegenerative Disorders Research Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montréal, QC H3A 2B4, Canada.
Structural Genomics Consortium - Neuro, McGill University, Montréal, QC H3A 2B4, Canada.

Classifications MeSH